CA Patent

CA3003721A1 — Inhibitors of ret to treat cancer

Assigned to Blueprint Medicines Corp · Expires 2017-05-11 · 9y expired

What this patent protects

Inhibitors of wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions. The invention more particularly relates to compounds of the following general formula: (see above formula) and pharma…

USPTO Abstract

Inhibitors of wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions. The invention more particularly relates to compounds of the following general formula: (see above formula) and pharmaceutically acceptable salts thereof. Compounds and compositions of the invention may be used for treating a subject suffering from a cancer mediated by a RET fusion or a RET mutation.

Drugs covered by this patent

Patent Metadata

Patent number
CA3003721A1
Jurisdiction
CA
Classification
—
Expires
2017-05-11
Drug substance claim
No
Drug product claim
No
Assignee
Blueprint Medicines Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.